TGTX
TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2024 Net Revenue and 2025 Anticipated Development Milestones
时间：2025-01-14 20:00:02 市场： 美股 综合
New Data for Briumvi® (Ublituximab-Xiiy) Demonstrate That 92% of Patients With Relapsing Multiple Sclerosis Were Free From Disability Progression After 5 Years of Treatment
时间：2024-09-18 19:03:08 市场： 综合 美股